Study of viral markers, clinical and biochemical profile of viral hepatitis in patients of alcoholic liver disease
Keywords:Alcoholic liver disease, Prevalence, SGPT, SGOT, Viral hepatitis
Background: There is a significant worldwide burden of Alcoholic Liver Disease (ALD). Both alcohol abuse and infection with hepatitis viruses can lead to liver disease. Alcohol and hepatitis viruses have synergistic effects in the development of liver disease. Thus, early detection of virus hepatitis and targeted interventions can improve prognosis in ALD.
Methods: This cross-sectional study was conducted among 180 patients coming to Baroda medical college and SSG hospital, Vadodara having alcoholic liver disease were studied and evaluated for markes of viral hepatitis and its clinical and biochemical profile in alcoholic liver disease.
Results: our study we had taken 180 patients of alcoholic liver disease out of which male were 92% and female were 8%. Prevalence of viral hepatitis was 27.7% in ALD patients. Out of which hepatitis E was 13% followed by hepatitis A 11%, hepatitis B 4.44% and least was Hepatitis C 0.5%. In clinical profile fever was significantly higher in patients of viral hepatitis with ALD than patients without viral hepatitis. Bilirubin was not significant differ in both groups of patients but SGOT and SGPT had higher values in patients of viral hepatitis with ALD and thus ratio of SGOT/SGPT was also affected due to higher value of SGOT and SGPT.
Conclusions: Alcohol consumption and hepatitis virus infection have a synergic hepatotoxic effect, and the coexistence of these factors increases the risk of advanced liver disease. Patients starting treatment for chronic viral hepatitis infection should be specifically advised to stop or reduce alcohol consumption because of its potential impact on treatment efficacy and adherence and may benefit from additional support during antiviral therapy specially in chronic hepatitis.
McCullough AJ, O'Connor JB. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93(11):2022.
World Health Organization. Fact Sheet-Alcohol, 2015.Available at: http://www.who.int/mediacentre/factsheets/fs349/en/. Accessed May 4, 2015
El Serag Hb. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroentrol. 2012;142(6):1264-73.
Dolganiuc A. Alcohol and viral hepatitis: role of lipid rafts. Alcohol Res: Curr Rev. 2015;37(2):299.
Barboza L, Salmen S, Teran-Angel G, Peterson DL, Berrueta L. A deficient translocation of CD3ζ, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection. Cellular Immunol. 2013;284(1-2):9-19.
Arora U, Mann A. Prevalence of hepatitis B virus, hepatitis C virus and HIV in patients of chronic liver disease in amritsar. J Ind Acad Clin Med. 2007;8(1):29-31.
Xess A, Kumar M, Minz S, Sharma HP, Shahi SK. Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Ind J Pathol Microbiol. 2001;44(3):253-5.
Guidelines for the screening, care and treatment of persons with hepatitis C infection. world health organisation; april:2014.
Silva HD, Vitarana T, Ratnatunga N, Breschkin A, Withane N, Kularatne WN. Prevalence of hepatitis C virus markers in Sri Lankan patients with alcoholic cirrhosis. J Gastroenterol Hepatol. 1994;9(4):381-4.
Rosman AS, Paronetto F, Galvin K, Williams RJ, Lieber CS. Hepatitis C virus antibody in alcoholic patients: association with the presence of portal and/or lobular hepatitis. Archiv Internal Med. 1993;153(8):965-9.
Suthar H, Suthar K, Mewada B. Clinical profile of cases of alcoholic liver disease. Int J Med Sci Public Health. 2013;2(2):408-12.